The Journal of dermatological treatment · 2025
Off-label use of upadacitinib in dermatology: a review.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Hongtao, Zhu Junkai, Ni Xiaoli, Yu Kaiyu, Mu Zhen
Аннотация
OBJECTIVES: Upadacitinib, a selective JAK1 inhibitor, is approved for the treatment of atopic dermatitis but is increasingly used off-label in dermatology. This study aimed to summarize the existing evidence on such off-label use to clarify its potential value and safety in dermatological practice.
METHODS: We identified 113 papers (n = 638) on the off-label use of upadacitinib for dermatological conditions via PubMed.
RESULTS: Our findings indicate that upadacitinib demonstrated potential efficacy in alopecia areata, vitiligo, lupus erythematosus, and other dermatoses. The most common upadacitinib dose is 15 mg/day. Common adverse events included elevated creatine kinase levels, infections, and acne.
CONCLUSIONS: While preliminary data show promising results, the evidence is limited to case reports and case series. Future randomized trials are needed to validate efficacy and safety.
METHODS: We identified 113 papers (n = 638) on the off-label use of upadacitinib for dermatological conditions via PubMed.
RESULTS: Our findings indicate that upadacitinib demonstrated potential efficacy in alopecia areata, vitiligo, lupus erythematosus, and other dermatoses. The most common upadacitinib dose is 15 mg/day. Common adverse events included elevated creatine kinase levels, infections, and acne.
CONCLUSIONS: While preliminary data show promising results, the evidence is limited to case reports and case series. Future randomized trials are needed to validate efficacy and safety.